Summary
Boston Scientific Corporation (BSX) announced the successful completion of its acquisition of Vertiflex, Inc. on June 11, 2019. This strategic move, previously announced in May 2019, signifies Boston Scientific's expansion into the interventional pain management market, specifically targeting patients suffering from lumbar spinal stenosis (LSS). Vertiflex's key product, the Superion® Indirect Decompression System, offers a minimally invasive solution to alleviate pain and improve physical function for this patient population. The acquisition is expected to enhance Boston Scientific's product portfolio in the pain management segment, a growing area within the medical device industry. Investors should view this as a positive step towards diversifying revenue streams and capitalizing on unmet needs in the treatment of LSS, a condition affecting a significant number of individuals.
Key Highlights
- 1Boston Scientific Corporation (BSX) has completed the acquisition of Vertiflex, Inc. as of June 11, 2019.
- 2The acquisition was initially announced on May 9, 2019.
- 3Vertiflex is known for its Superion® Indirect Decompression System.
- 4The Superion® system is a minimally-invasive device for treating lumbar spinal stenosis (LSS).
- 5This acquisition expands BSX's presence in the interventional pain management market.
- 6The closing of the acquisition followed the satisfaction of customary closing conditions.
- 7A press release regarding the acquisition closing is included as an exhibit.